• Topics

  • Formats

High drug pricing is an important issue at the intersection of healthcare, economics, and ethics. The increasing cost of pharmaceuticals, advanced therapy medicinal products (ATMPs), and more personalized treatment options jeopardizes the accessibility and affordability of interventions that are sometimes lifesaving globally. Increased drug pricing is increasingly leading to unaffordable treatments even in affluent societies.

The prospect for the near future, with treatment prices per patient soaring and negative reimbursement decisions solely based on failed pricing negotiations is negative. This polarizes the discussion between different stakeholders including patients, health care providers, pharmaceutical companies, regulatory agencies, Health Technology Assessment (HTA) agencies, patient advocacy groups, payers (insurers and governments), (bio)ethicists, shareholders, academia, and Non-Governmental Organizations (NGOs) and international bodies. Unfortunately, these discussions are often emotional.

We discuss a method to rationalize the debate by explicitly incorporating uncertainties in value estimations throughout the drugs lifecycle.

Reading this content is completely free

Enjoy Unlimited Access and Unlock
Additional Features with a Free Account

Join Now

You are attempting to log out of MyMA

Do you really want to log out?